Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

NEW YORK--(BUSINESS WIRE) May 26, 2022 -- Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials